What happened Shares of GoodRx Holdings (NASDAQ: GDRX) fell 10.7% through the first half of 2021, according to data from S&P Global Market Intelligence. The stock had been up as much as 40% year to date in February before a broad sell-off in technology stocks. It continued to trend down as Amazon (NASDAQ: AMZN) introduced new features to its online pharmacy and GoodRx user growth slowed considerably. GDRX data by YCharts. So what Amazon launched its online pharmacy in the U.S. late last year. In May, it released two price-comparison features that take direct aim at GoodRx. The first allows members of the company's Prime service to search for drug prices at Amazon along with 60,000 other pharmacies. The second helps users figure out how much they will have to pay for a drug based on their insurance co-pay. Both tools help Amazon keep the pharmacy orders of Prime members in-house more often. Image source: Getty Images. What might concern Wall Street even more is the deceleration in growth of monthly active consumers (MAUs). In 2019, GoodRx averaged 58% year-over-year growth in MAUs for the four quarters. In 2020, that slowed to 35%. Investors who were eager to get a read on normalized growth coming out of the pandemic weren't happy with what they saw. Management reported year-over-year MAUs grew just 17% in the first quarter of 2021. It was just 1% compared to the final quarter of 2020. That translated to only 20% revenue growth compared to 42% in 2020. Now what The user number will be on investors' radar when the company reports earnings in mid-August. Management has called for 41% revenue growth in the second quarter as it expects to return to last year's pace. The company acquired HealthiNation, a healthcare consumer-education platform, in April and price comparator RxSaver in May. It is counting on these, as well as services like telehealth and partnerships with pharmaceutical companies, to reaccelerate growth. What management has to say in a few weeks will likely determine whether the stock price can recapture its February highs before the end of 2021. 10 stocks we like better than GoodRx Holdings, Inc.When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and GoodRx Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon. The Motley Fool recommends GoodRx Holdings, Inc. and recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool has a disclosure policy.Source